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21 ABSTRACT
22 There is a limited understanding of how genetic loci associated with glycemic traits and type 2 
23 diabetes (T2D) influence the response to anti-diabetes medications. Polygenic scores provide 
24 increasing power to detect patterns of disease predisposition that might benefit from a targeted 
25 pharmacologic intervention. In the Study to Understand the Genetics of the Acute Response to 
26 Metformin and Glipizide in Humans (SUGAR-MGH), we constructed weighted polygenic scores 
27 using known genome-wide significant associations for T2D, fasting glucose (FG), and fasting 
28 insulin (FI), comprised of 65, 43, and 13 single nucleotide polymorphisms, respectively. Multiple 
29 linear regression tested for associations between scores and glycemic traits as well as 
30 pharmacodynamic endpoints, adjusting for age, sex, race, and body mass index (BMI). A higher 
31 T2D score was nominally associated with a shorter time to insulin peak, greater glucose area over 
32 the curve, shorter time to glucose trough, and steeper slope to glucose trough after glipizide. In 
33 replication, a higher T2D score was associated with a greater 1-year HbA1c reduction to 
34 sulfonylureas in the Genetics of Diabetes Audit and Research, Tayside and Scotland (GoDARTS) 
35 study (p=0.02). Our findings suggest that individuals with a higher genetic burden for T2D 
36 experience a greater acute and sustained response to sulfonylureas. 
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37 Metformin and sulfonylureas are widely prescribed medications for the treatment of type 
38 2 diabetes (T2D). Metformin is the recommended first-line agent for T2D, owing to its high 
39 efficacy, low cost, and favorable side effect profile (1). Sulfonylureas are another commonly 
40 employed agent due to their wide availability and glucose-lowering ability through stimulation of 
41 insulin secretion from pancreatic β cells (2). Despite the recommendation that careful 
42 consideration of patient factors should inform the choice of therapy (3), clinicians typically do not 
43 account for the molecular target of each drug or integrate information about an individual’s genetic 
44 profile when prescribing a medication. 
45 In the last decade, large-scale genome-wide association studies (GWAS) and high-
46 throughput sequencing studies have identified over 700 genetic signals influencing T2D risk and 
47 glycemic traits (4-10). The expanding list of genetic variants has resulted in a better understanding 
48 of the disease pathophysiology of T2D and the major processes that contribute to disease risk. 
49 However, the impact of these genetic loci on the response to pharmacological interventions for 
50 T2D has been less systematically studied. 
51 With regards to metformin response, candidate gene studies have yielded initial findings 
52 in transporter gene variants (SLC22A1, SLC47A1) but findings were not validated in subsequent 
53 large-scale meta-analyses (11). GWAS and meta-analyses have revealed additional loci, including 
54 single nucleotide polymorphisms (SNPs) in or near the gene encoding ataxia-telangiectasia 
55 mutated kinase (ATM) (12) and in an intron SNP of the glucose transporter GLUT2 (SLC2A2) 
56 (13). Pharmacogenetic studies of sulfonylurea response have been limited to candidate gene 
57 studies, and no GWAS for sulfonylurea response has been published to date (14-17).
58 The impact of T2D-associated genetic variants on drug response has been investigated as 
59 well. In particular, TCF7L2, the gene harboring common genetic variants with the largest effect 
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60 on T2D susceptibility discovered to date, has been associated with drug response to sulfonylureas 
61 in those with established T2D (18) and in those at risk of T2D (19). For metformin, TCF7L2 has 
62 been associated with glycemic response in the early stages of disease (19, 20). Because individual 
63 variants only have a modest effect, the field is now embracing the use of polygenic scores of 
64 aggregated variants, which offer increasing power and capture a greater proportion of the variance 
65 explaining a given trait (21).
66 As such, we examined whether polygenic scores derived from genome-wide significant 
67 loci for glycemic traits and T2D are associated with glycemic traits and the response to metformin 
68 and glipizide in the Study to Understand the Genetics of the Acute Response to Metformin and 
69 Glipizide in Humans (SUGAR-MGH). We hypothesized that polygenic scores constructed based 
70 on previously known genome-wide associations with fasting glucose (FG) and fasting insulin (FI) 
71 would be associated with these glycemic traits in SUGAR-MGH. Furthermore, we expected that 
72 a genetic predisposition to insulin secretion or action would influence the human response to 
73 glipizide or metformin, respectively. For findings that reached significance, we sought replication 
74 in the Genetics of Diabetes Audit and Research, Tayside and Scotland (GoDARTS) study, a 
75 longitudinal cohort study of T2D. 
76 RESEARCH DESIGN AND METHODS
77 Study design and participants
78 The study design of SUGAR-MGH has been previously described (22). Briefly, 1,000 
79 participants were enrolled at three Boston academic medical centers between 2008-2015. 
80 Participants were preferentially enrolled in the study if they had risk factors for T2D (i.e. metabolic 
81 syndrome, obesity, polycystic ovarian syndrome, history of gestational diabetes, positive family 
82 history) or lifestyle-controlled T2D. Some participants had previously unknown T2D, diagnosed 
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83 at the time of study entry. All participants were naïve to metformin and glipizide. Informed consent 
84 was obtained from all study participants and the study protocol was approved by the Partners 
85 Human Research Committee (Partners HealthCare, Boston, MA).
86 After an overnight fast of at least 8 hours, participants received a single dose of 5 mg 
87 glipizide if their fasting blood glucose was >4.4 mmol/L (Visit 1). This threshold was chosen to 
88 minimize the risk of hypoglycemia. Glucose and insulin levels were subsequently measured at 
89 baseline, 30, 60, 90, 120, 180, and 240 minutes. The period of observation following glipizide 
90 administration was terminated early if the participant developed neuroglycopenic symptoms, a 
91 blood glucose ≤2.77 mmol/L with symptoms of hypoglycemia, blood glucose <2.50 mmol/L with 
92 or without symptoms of hypoglycemia, or at the discretion of study staff based on clinical 
93 assessment. Subjects who did not meet the threshold to receive glipizide or terminated the glipizide 
94 challenge early were excluded from analyses of glipizide response. Five days later, participants 
95 received a two-day course of 500 mg metformin twice daily, followed by a 75-g oral glucose 
96 tolerance test (OGTT) at Visit 2. Plasma glucose was measured by a hexokinase assay (Roche, 
97 Indianapolis, IN) and insulin was determined using a radioimmunoassay (Beckman Coulter, 
98 Fullerton, CA). 
99 GoDARTS is a longitudinal case-control study that was established to study the genetics 
100 of T2D. Over 18,000 participants were enrolled between December 1998 and August 2012, of 
101 whom half were diagnosed with T2D and the remaining age- and sex-matched non-diabetic 
102 controls were identified from general practice records in Tayside, Scotland. Details of the cohort 
103 have been previously described (23). The GoDARTS study was approved by the Tayside 
104 Committee for Medical Research Ethics. Written informed consent was obtained from each 
105 participant.
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106 For the replication analysis, we evaluated participants in GoDARTS who were diagnosed 
107 with T2D and were either on a sulfonylurea as monotherapy or as an add-on to metformin. Subjects 
108 with a history of insulin use, T2D diagnosed before 35 years of age, and with a baseline 
109 hemoglobin A1c (HbA1c) <7% (53 mmol/mol) or >14% (130 mmol/mol) were excluded.
110 Genotyping
111 In SUGAR-MGH, DNA was extracted and genotyping was performed using the iPLEX-
112 GOLD Assay from Sequenom by allele-specific primer extension of amplified products with 
113 detection by mass spectroscopy (24). Hardy-Weinberg equilibrium was tested within each self-
114 described ethnic group. SNPs with call rates <95% and samples with call rates <95% were 
115 excluded. 
116 Genotyping and quality control of the GoDARTS data have been described previously (12, 
117 13). The SNPs included in the polygenic scores tested in this study were extracted from existing 
118 GWAS data. Imputed SNPs had an imputation score >0.9.
119 Polygenic score construction
120 Polygenic scores were constructed for T2D, FG, and FI by summing the number of risk 
121 alleles carried by each individual, weighted by the effect size estimates from well-established 
122 genome-wide significant associations derived from the Meta-Analyses of Glucose and Insulin-
123 related traits Consortium (MAGIC) or Europeans in the DIAbetes Meta-ANalysis of Trans-Ethnic 
124 association studies (DIAMANTE) Consortium (4, 6, 8). Due to the limited availability of SNPs on 
125 our genotyping platform in SUGAR-MGH, we were able to include only a subset of the known 
126 genome-wide significant loci for T2D and glycemic traits, resulting in a T2D polygenic score of 
127 65 SNPs, FG score of 43 SNPs, and FI score of 13 SNPs. Supplemental Tables S1-3 list the genetic 
128 variants, corresponding genes, and original GWAS references for each score. Effect alleles were 
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129 defined as T2D risk-raising, FG-raising, and FI-raising alleles. We utilized the 1000Genomes 
130 database for global frequencies of the effect alleles because the individuals in SUGAR-MGH were 
131 largely without overt T2D, and we wanted to avoid using a reference database that included 
132 individuals from several T2D cohorts. If the lead SNP was not available, we utilized a proxy that 
133 had an r2 > 0.8 for Europeans. In GoDARTS, polygenic scores were created in the same manner.
134 Statistical analyses
135 In SUGAR-MGH, the area over the curve (AOC) for decreases in glucose during the 
136 glipizide challenge was calculated by subtracting glucose area under the curve (AUC) by the 
137 trapezoidal method from the baseline glucose value × total time for the glipizide challenge. The 
138 AUC for glucose and insulin following metformin administration was calculated by the trapezoidal 
139 method, which accounted for baseline glucose and insulin values, respectively. Insulin resistance 
140 by homeostasis model assessment (HOMA-IR) was calculated as previously described (25). 
141 Missing data were not imputed. 
142 The mean ± standard deviation or median (interquartile range) are reported for continuous 
143 normally or non-normally distributed traits, respectively. Assessment of normality was performed 
144 using the Shapiro-Wilk test. Multiple linear regression with adjustments for age, sex, self-reported 
145 race/ethnicity, and body mass index (BMI) were used to test the association between each 
146 polygenic score and glycemic traits as well as pharmacodynamic endpoints. β coefficients are 
147 presented as the incremental increase or decrease in the trait or endpoint per standard deviation of 
148 the tested polygenic score. We assessed for both nominal significance (p<0.05) and a more 
149 stringent p-value of 0.008 for multiple comparisons (two drugs × three polygenic scores). 
150 Statistical analyses were performed using R 3.5.2 (26).
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151 For the replication analyses in GoDARTS, multiple linear regression tested for the 
152 association between polygenic score and the outcome of HbA1c reduction, defined as baseline 
153 HbA1c (measured within 180 days prior to sulfonylurea initiation) minus on-treatment HbA1c at 
154 one year. Additional covariates included baseline HbA1c, age at diagnosis of diabetes, sex, BMI, 
155 average sulfonylurea dose, and mediation adherence as previously described (18). 
156 Data and Resource Availability
157 The datasets analyzed during the current study are available from the corresponding author upon 
158 reasonable request. Data from SUGAR-MGH are also available at Clinicaltrials.gov.
159 RESULTS
160 Subject characteristics
161 The baseline characteristics of the 1,000 participants in SUGAR-MGH are summarized in 
162 Table 1. Approximately half of participants were female, the mean age was 47.2 years, and over 
163 35% of participants came from ethnic minority populations. The mean BMI was 30.2 kg/m2 and 
164 mean fasting glucose was 5.16 mmol/L, consistent with a population at risk of requiring future 
165 anti-diabetic agents. Only 26 participants had a diagnosis of T2D (not treated pharmacologically) 
166 at the time of study entry. Of the 1,000 participants, 351 were either ineligible for the glipizide 
167 challenge due to low fasting glucose or terminated the challenge early in accordance with study 
168 protocol.
169 Construction of polygenic scores for T2D, FG, and FI
170 The distribution of all three polygenic scores is depicted in Figure 1. The mean T2D 
171 polygenic score was 61.82 (range 44.49-80.93). The mean FG polygenic score was 48.92 (range 
172 31.58-66.08). The mean FI polygenic score was 12.54 (range 5.11-22.74). 
173 Association between polygenic scores and baseline glycemic traits
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174 Table 2 shows the associations between each polygenic score and either FG or FI at 
175 baseline in SUGAR-MGH. The FG polygenic score was strongly associated with FG in our cohort 
176 in multivariate analyses (p<0.001), with each standard deviation increase in score raising FG by 
177 0.13 mmol/L. This association was present in stratified analyses of the non-Hispanic white 
178 (β=0.09, p=0.01) and non-Hispanic black (β=0.14, p=0.007) individuals in SUGAR-MGH. 
179 Likewise, a higher FI polygenic score was associated with higher FI (p=0.04); this finding was 
180 also present in stratified analyses of non-Hispanic whites. A higher T2D polygenic score trended 
181 toward significance (p=0.05) for the association with higher FG but was not associated with FI.
182 Association between T2D score and the acute response to glipizide and metformin 
183 Table 3 summarizes the association between T2D polygenic score and select endpoints of 
184 glipizide and metformin response. A higher T2D polygenic score was associated with a greater 
185 glucose AOC, shorter time to glucose trough, steeper slope to glucose trough, and shorter time to 
186 insulin peak following glipizide administration at nominal significance (p<0.05). When the more 
187 stringent p-value of 0.008 was utilized to correct for multiple comparisons, the finding involving 
188 the insulin-based endpoint remained significant. We tested and did not find a significant 
189 association between T2D polygenic score and pharmacodynamic endpoints of metformin response 
190 (change in FG, change in FI, change in HOMA-IR; Table 3). 
191 Given that the T2D polygenic score was constructed using effect size estimates for 
192 European ancestries and proxies were selected based on linkage disequilibrium in Europeans, we 
193 performed stratified analyses for the non-Hispanic white and black participants separately. In the 
194 non-Hispanic white subset of SUGAR-MGH (Supplemental Table S4), we observed that 
195 individuals with a higher T2D polygenic score trended toward having a greater glucose AOC and 
196 shorter time to insulin peak, though this did not reach our significance threshold after adjustment 
Page 9 of 35
For Peer Review Only
Diabetes
197 for multiple testing. Similarly in the non-Hispanic black participants, a similar direction of 
198 association was seen between a higher T2D polygenic score and shorter time to glucose trough 
199 and insulin peak following glipizide (Supplemental Table S5). The relationship between higher 
200 T2D polygenic score and steeper slope to glucose trough trended toward but did not reach 
201 significance in both subgroups.  
202 Association between glycemic trait polygenic scores and the acute response to glipizide and 
203 metformin 
204 Additionally, we observed associations between glycemic trait scores and endpoints of 
205 glipizide response, reaching only nominal significance but not meeting the more stringent 
206 significance threshold after adjustment for multiple testing. A higher FG polygenic score trended 
207 toward a higher glucose AOC (p=0.02), with each standard deviation increase in score raising the 
208 glucose AOC by 10.82 mmol/L*min (Supplemental Table S6). Moreover, each standard deviation 
209 increase in FI polygenic score trended toward a 0.05 mmol/L higher glucose trough following 
210 glipizide administration (p=0.02, Supplemental Table S7). No association was observed between 
211 either glycemic trait polygenic score and select endpoints of metformin response (Supplemental 
212 Tables S6-7). 
213 Replication in GoDARTS
214 The baseline characteristics of the 2,228 individuals in GoDARTS who underwent 
215 treatment with a sulfonylurea are summarized in Table 4. Approximately half of participants were 
216 female, the mean age was 59.7 years, and the baseline HbA1c was 8.97% (75 mmol/mol). All 
217 subjects were of European ancestry. To replicate our findings in SUGAR-MGH with respect to 
218 sulfonylurea response, we constructed a weighted T2D polygenic score for each individual in 
219 GoDARTS and tested for association with the HbA1c reduction over one year. The mean T2D 
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220 polygenic score was 74.92 (range 53.29-93.08) with a standard deviation of 5.90. In adjusted 
221 analyses, for each standard deviation increase in T2D score, there was a 0.063% (0.07 mmol/mol) 
222 greater HbA1c reduction in response to sulfonylurea therapy (p=0.02). Moreover, those in the top 
223 decile of T2D polygenic score had a 0.27% ± 0.12% greater HbA1c reduction compared to those 
224 in the bottom decile (p=0.03). 
225 DISCUSSION
226 In SUGAR-MGH, we built polygenic scores for elevated T2D risk, FG, and FI using 
227 genome-wide significant variants discovered in GWAS for T2D and glycemic traits. We first 
228 assessed whether the three polygenic scores were associated with glycemic traits, which would 
229 indicate the generalizability of these scores to outcomes in this cohort. Subsequently we tested the 
230 hypothesis that combining individual variants into a polygenic score may provide additional 
231 information on patterns of T2D disease predisposition that may benefit from tailored 
232 pharmacologic intervention. 
233 We indeed demonstrated that sets of genome-wide significant genetic variants confirmed 
234 to be associated with glycemic traits were associated with fasting glucose and insulin levels in 
235 SUGAR-MGH. Our findings were consistent in direction with and stronger in significance than 
236 previously reported findings in an interim analysis conducted for our design paper at two-thirds 
237 study enrollment in SUGAR-MGH (22). Additionally, we examined whether a polygenic score for 
238 T2D risk would be associated with the same glycemic traits in our cohort. We found that there was 
239 a trend toward higher FG in those with a higher genetic burden for T2D, possibly related to the 
240 overlap of 14 SNPs between the T2D and FG scores. No association was seen between T2D 
241 polygenic score and FI, but this was not unexpected given that many of the genetic polymorphisms 
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242 in the T2D score were those that directly or indirectly affect pancreatic β-cell function rather than 
243 insulin resistance. 
244 We also tested the associations between each of the three polygenic scores and phenotypes 
245 of glipizide and metformin response. Individuals with a higher genetic burden for T2D were found 
246 to have a more robust response to glipizide, as indicated by a larger glucose AOC, representing a 
247 greater cumulative drop in glucose over time. Additionally, a higher T2D score was associated 
248 with a shorter time to glucose trough, steeper slope to glucose trough, and shorter time to insulin 
249 peak, all consistent with an enhanced glipizide response. We note that these findings were all at 
250 nominal significance (p<0.05). Since the outcomes are correlated, we subsequently accounted for 
251 multiple comparisons, after which only the insulin-based outcome remained statistically 
252 significant. However, the presence of associations between T2D polygenic score and several 
253 glipizide challenge endpoints provides evidence for a true impact on glipizide response. These 
254 findings are additionally supported by the observation of a marginally higher glucose AOC in 
255 individuals with a higher FG polygenic score, again indicative of a greater glipizide response. 
256 Since many of the SNPs comprising the T2D polygenic score influence β-cell function, it 
257 appears that treatment with glipizide, a sulfonylurea that stimulates insulin secretion from the β 
258 cell, can overcome these genetic defects in the early stages of T2D pathogenesis. We speculate 
259 that perhaps those with a higher risk of T2D may have overly sensitized β cells compared with 
260 those with a lower polygenic score, resulting in an accentuated response to glipizide. This is similar 
261 to what is observed in maturity-onset diabetes of the young (MODY) type 3, which is characterized 
262 by HNF1A mutations causing decreased insulin secretion. Individuals with MODY3 demonstrate 
263 a heightened sensitivity to sulfonylureas (27) but require insulin as the secretory defect progresses. 
264 We hypothesize that individuals with a higher T2D risk score may behave in the same way, 
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265 whereby they initially have a sensitized β cell early in the disease course but may achieve β-cell 
266 failure sooner. 
267 Based on our findings, we sought replication in GoDARTS, a case-control study of T2D 
268 with longitudinal clinical and genetic data available. For a subset of 2,228 individuals who 
269 received a sulfonylurea, we tested whether a T2D polygenic score is associated with a clinical drug 
270 response. We found that the mean T2D polygenic score was higher in GoDARTS than in SUGAR-
271 MGH, illustrating a higher burden of T2D risk variants. This was expected since GoDARTS 
272 participants have established T2D requiring sulfonylurea therapy. Moreover, we observed that a 
273 higher T2D score was again significantly associated with a greater sulfonylurea response, as 
274 measured by HbA1c reduction at one year. Thus, we demonstrated that the T2D score was not 
275 only associated with the physiologic response to an acute dose of glipizide, but also influenced the 
276 sustained glycemic response to sulfonylureas. We acknowledge that a 0.063% greater reduction in 
277 HbA1c per standard deviation increase in T2D score is clinically small; however, this difference 
278 was as high as 0.27% when comparing the top and bottom deciles in T2D score. Therefore, the 
279 clinical utility of the T2D polygenic score may be limited in most of the population, but becomes 
280 more relevant in those at the extremes. 
281 Interestingly, our findings appear to be in contrast with the candidate gene analysis of the 
282 TCF7L2 variant rs7903146 in GoDARTS, in which homozygotes for the T risk allele were less 
283 likely to respond to sulfonylureas (18). We have previously postulated that this genotype may have 
284 a differential effect in individuals with T2D who already have some degree of β-cell dysfunction 
285 compared with those without overt T2D (19). One might expect that similarly those with a high 
286 T2D score and a predisposition to β-cell failure would benefit from sulfonylureas early in the 
287 disease course and have an attenuated response over time. However, our replication analyses in 
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288 GoDARTS suggest otherwise, in that the association between a higher T2D score and greater 
289 response to sulfonylureas is observed even in those with established T2D and an average duration 
290 of disease of 4.8 years. Whether this effect would be observed for those with an even longer 
291 duration of T2D remains to be determined. If so, this could suggest that the T2D polygenic score 
292 captures additional mechanisms that remain to be elucidated. 
293 We also demonstrated that individuals with a higher FI polygenic score trended toward a 
294 higher glucose trough, adjusted for baseline glucose, in response to glipizide. This finding might 
295 suggest that for the same 5 mg dose of glipizide resulting in the same amount of insulin secretion, 
296 individuals with a higher degree of insulin resistance respond worse and have a smaller glucose-
297 lowering response. Notably, this observation was present after adjustment for BMI but did not 
298 meet the more stringent p-value for multiple comparisons. We also did not observe an effect on 
299 other glipizide challenge endpoints.
300 With respect to metformin, we did not observe any significant associations between 
301 polygenic score and phenotypic endpoints of metformin response. This is not surprising, especially 
302 as T2D and FG polygenic scores comprising of predominantly β-cell function SNPs would not be 
303 expected to associate with metformin response. Similarly in the Diabetes Prevention Program 
304 (DPP), a pre-diabetic cohort, a genetic score of 34 T2D loci was associated with an increased risk 
305 of progression to diabetes and a lower probability of regression to normoglycemia, but there was 
306 no observed interaction effect of metformin on this association (28).
307 Prior pharmacogenetic studies of sulfonylurea response have been limited to candidate 
308 gene studies (14-17), and few have examined individual T2D-associated genes (18, 19). Our study 
309 is the first, to our knowledge, to show a significant association between an aggregate score of T2D 
310 risk loci and drug response prospectively. One recently published study by Martono et al. 
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311 examined the added utility of genetic risk scores for insulin sensitivity, β-cell function, and T2D 
312 for prediction of the initial response to metformin or sulfonylureas in a primary care population 
313 with early T2D (29). They did not find an association between any of these scores and drug 
314 response, as measured by 6-month HbA1c, adjusted for baseline HbA1c. However, the study 
315 population was considerably smaller than ours (only 282 individuals initiating metformin and 89 
316 individuals starting sulfonylureas) and may have been underpowered to detect significant effects. 
317 We note that our study also utilized weighted polygenic scores and data from the most recent 
318 GWAS for T2D (8).
319 Study strengths include the diverse population of our cohort, which allow for 
320 generalizability of our findings. Furthermore, SUGAR-MGH was conducted under fasting 
321 conditions, which limited the influence of dietary and lifestyle habits. While SUGAR-MGH had 
322 the advantage of examining a physiologic response to an acute perturbation in a controlled 
323 environment, the study design did not include an OGTT prior to metformin administration, which 
324 would have provided a dynamic glucose challenge for assessing metformin response.  
325 Another shortcoming is that we were only able to assess a fraction of the known genomic 
326 loci for T2D and glycemic traits, due to the limited availability of SNPs on our genotyping 
327 platform. Genome-wide genotyping is currently underway in SUGAR-MGH, which will permit 
328 more extensive polygenic score construction in the future. This will include partitioned polygenic 
329 scores, which group variants by a common biological process and can provide insight into disease 
330 pathophysiology. The current study only analyzed restricted-to-significant polygenic scores, and 
331 future studies examining global extended polygenic scores, generated from large numbers of 
332 subthreshold significant variants, are needed as well. However, there appears to be limited 
333 improvement in predictive performance between a restricted polygenic score comprising 199 SNPs 
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334 and a global polygenic score (21). These findings suggest that there may not be a significant step-
335 up in power with increasing the number of variants included in the polygenic score. Finally, we 
336 note that the effect size estimates used in the polygenic score construction are for European 
337 ancestry, which does not take into consideration that risk variants can have different effect sizes 
338 in different populations. We also do not have ancestry information available on those individuals 
339 who self-reported as “black” in our cohort. However, in our stratified analyses in non-Hispanic 
340 white and black individuals (comprising 64% and 21% of SUGAR-MGH, respectively), we report 
341 findings that trend in the same direction as our primary analyses concerning the impact of the T2D 
342 polygenic score on glipizide response.  
343 In summary, our findings suggest that there is some overlap between genes implicated in 
344 the risk of developing T2D and those associated with the response to treatment with sulfonylureas. 
345 We add to the growing body of literature on the potential utility of polygenic scores in 
346 understanding the response to T2D pharmacotherapy. Our study provides preliminary evidence 
347 that sulfonylureas could be more effective in T2D risk allele carriers, both in drug-naïve 
348 individuals as well as those with established T2D. This finding is consistent with the recent results 
349 reported by Dennis et al. in the ADOPT trial, showing that participants who cluster in the severely 
350 insulin deficient diabetes phenotype (presumably enriched for beta-cell deleterious alleles) 
351 experience a robust initial response to sulfonylureas, though it worsens over time (30). While 
352 genetic variation has been shown to alter the response to therapy in T2D, further confirmatory 
353 studies are necessary to clarify the role of polygenic scores in clinical decision-making. 
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451 TABLES
452 Table 1. Demographic characteristics and baseline measurements of 1,000 participants in 
453 SUGAR-MGH
All participants (n=1,000)
Female (n, %) 539 (54%)
Age (years) 47.2 ± 16.2
BMI (kg/m2), n=978 30.2 ± 7.1
Self-reported race/ethnicity (n, %)
     White, non-Hispanic 639 (64%)
     Black, non-Hispanic 209 (21%)
     Hispanic 69 (6.9%)
     Asian, non-Hispanic 59 (5.9%)
     Others 24 (2.4%)
Diagnosis of type 2 diabetes 26 (2.6%)
Fasting glucose (mmol/L) 5.16 ± 0.93
Fasting insulin (pmol/L), n=970 3.56 (3.03, 4.11)
454 Age, body mass index (BMI), and fasting glucose are shown as mean ± standard deviation. 
455 Fasting insulin is presented as median (interquartile range). 
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456 Table 2. Association of polygenic scores with baseline glycemic traits in SUGAR-MGH
Polygenic score Trait β (95% CI) P
Fasting glucose Fasting glucose (mmol/L) 0.13 (0.07, 0.18) <0.001
Fasting insulin Ln fasting insulin (pmol/L) 0.05 (0.003, 0.10) 0.04
Type 2 diabetes Fasting glucose (mmol/L) 0.05 (-2.1e-5, 0.10) 0.05
Type 2 diabetes Ln fasting insulin (pmol/L) 0.009 (-0.04, 0.06) 0.71
457 Linear regression model was adjusted for age, sex, race/ethnicity, and body mass index (BMI). β 
458 values are reported per standard deviation of polygenic score.
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459 Table 3. Association of T2D polygenic score with glipizide and metformin endpoints in 
460 SUGAR-MGH
N β (95% CI) P§
Glipizide endpoint*
Glucose trough (mmol/L)† 639 -0.01 (-0.05, 0.02) 0.50
Glucose AOC (mmol/L*min) 633 10.05 (1.17, 18.93) 0.03
Time to glucose trough (min)† 639 -4.88 (-8.82, -0.94) 0.02
Slope to glucose trough (mmol/L/min)† 638 7.6e-4 (1.2e-4, 1.4e-3) 0.02
Ln peak insulin (pmol/L)‡ 615 0.04 (-0.009, 0.09) 0.11
Time to insulin peak (min)‡ 615 -5.83 (-9.91, -1.76) 0.005
Slope to insulin peak (pmol/L/min)‡ 609 -0.11 (-0.33, 0.12) 0.35
Metformin endpoint
Fasting glucose V2-V1 (mmol/L)† 924 -0.009 (-0.04, 0.02) 0.56
Glucose AUC (mmol/L*min) 900 6.79 (-3.20, 16.77) 0.18
Fasting insulin V2-V1 (pmol/L)‡ 891 -3.11 (-6.74, 0.52) 0.09
Insulin AUC (pmol/L*min) 831 -66.27 (-2561.34, 1640.89) 0.67
Ln HOMA-IR V1 (mmol*pmol/L2) 915 0.02 (-0.03, 0.08) 0.44
Ln HOMA-IR V2 (mmol*pmol/L2) 914 -0.01 (-0.07, 0.05) 0.69
HOMA-IR V2-V1 (mmol*pmol/L2) 914 -0.84 (-1.73, 0.04) 0.06
461 V1=visit 1, V2=visit 2, AOC=area over the curve, AUC=area under the curve. *351 individuals 
462 did not meet the threshold to receive glipizide or terminated the glipizide challenge early and 
463 were excluded from analyses of glipizide response. †Adjusted for baseline glucose. ‡Adjusted for 
464 ln baseline insulin. Linear regression model was adjusted for age, sex, race/ethnicity, and body 
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465 mass index (BMI). §P-values of <0.008 are reported in bold and reflect significance after 
466 adjustment for multiple testing.
467
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477 Age, BMI, and HbA1c values are presented as mean ± standard deviation. 
All participants (n=2,228)
Age at diagnosis (years) 59.7 ± 10.3
Sex (% female) 45%
Duration of diabetes (years) 4.8 ± 4.4
Baseline BMI (kg/m2)/ 30.5 ± 5.4
Baseline HbA1c (%) 8.97 ± 1.47
On-treatment HbA1c (%) 7.64 ± 1.40
Average HbA1c reduction (%) 1.34 ± 1.69
Sulfonylurea adherence (%) 86% ± 20%
Sulfonylurea monotherapy (%) 44%
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479 FIGURE LEGEND
480 Figure 1. Distribution of polygenic scores for (A) type 2 diabetes, (B) fasting glucose, (C) 
481 fasting insulin across 1,000 individuals in SUGAR-MGH.
Page 25 of 35






























































Page 26 of 35




Supplemental Table S1. Genetic variants included in the T2D polygenic score. 




rs340879a PROX1 1 214156514 C 0.508 0.059 Morris et al. 2012
rs17106184 FAF1 1 50909985 G 0.921 0.063 Mahajan et al. 2014
rs340874 PROX1 1 214159256 C 0.376 0.068 Dupuis et al. 2010
rs10195252 COBLL1 2 165513091 T 0.603 0.06 Scott et al. 2012
rs1260326 GCKR 2 27730940 C 0.707 0.067 Saxena et al. 2010
rs2943641 IRS1 2 227093745 C 0.751 0.094 Rung et al. 2009
rs3923113 GRB14 2 165501849 A 0.615 0.056 Kooner et al. 2011
rs7578326 IRS1 2 227020653 A 0.714 0.079 Voight et al. 2010
rs7578597 THADA 2 43732823 T 0.863 0.12 Zeggini et al. 2008
rs7607980 COBLL1 2 165551201 T 0.893 0.084 Manning et al. 2012
rs243021 BCL11A 2 60584819 A 0.496 0.058 Voight et al. 2010
rs11708067 ADCY5 3 123065778 A 0.850 0.089 Dupuis et al. 2010
rs2877716b ADCY5 3 123094451 C 0.811 0.086 Morris et al. 2012
rs13094957c UBE2E2 3 23457080 T 0.745 0.071 Morris et al. 2012
rs1801282 PPARG 3 12393125 C 0.930 0.1 Altshuler et al. 2000
rs4402960 IGF2BP2 3 185511687 T 0.389 0.11 Morris et al. 2012
rs4607103 ADAMTS9 3 64711904 C 0.646 0.052 Zeggini et al. 2008
rs6795735 ADAMTS9 3 64705365 C 0.287 0.048 Zeggini et al. 2008
rs16861329 ST6GAL1 3 186666461 C 0.835 0.057 Kooner et al. 2011
rs6446482 WFS1 4 6295693 G 0.721 0.085 Morris et al. 2012
rs6813195 TMEM154 4 153520475 C 0.592 0.055 Mahajan et al. 2014
rs4457053 ZBED3 5 76424949 G 0.203 0.059 Voight et al. 2010
rs459193 ANKRD55 5 55806751 G 0.606 0.073 Morris et al. 2012
rs4865796 ARL15 5 53272664 A 0.760 0.051 Scott et al. 2012
rs10946398 CDKAL1 6 20661034 C 0.405 0.12 Zeggini et al. 2008
rs9368222 CDKAL1 6 20686996 A 0.269 0.14 Scott et al. 2012
rs17168486 DGKB 7 14898282 T 0.272 0.069 Morris et al. 2012
rs2191349 DGKB 7 15064309 T 0.572 0.066 Dupuis et al. 2010
rs4607517 GCK 7 44235668 A 0.143 0.055 Dupuis et al. 2010
rs972283 KLF14 7 130466854 G 0.693 0.012 Voight et al. 2010
rs3802177d SLC30A8 8 118185025 G 0.744 0.11 Morris et al. 2012
rs516946 ANK1 8 41519248 C 0.804 0.08 Morris et al. 2012
rs896854 TP53INP1 8 95960511 T 0.484 0.05 Voight et al. 2010
rs10811661 CDKN2A/B 9 22134094 T 0.824 0.16 Morris et al. 2012
rs2796441 TLE1 9 84308948 G 0.603 0.066 Morris et al. 2012
rs13292136 TLE4 9 81952128 C 0.898 0.085 Voight et al. 2010
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rs1111875 HHEX 10 94462882 C 0.544 0.11 Morris et al. 2012
rs11257655 CDC123 10 12307894 T 0.301 0.09 Zeggini et al. 2008
rs12571751 ZMIZ1 10 80942631 A 0.535 0.07 Morris et al. 2012
rs7903146 TCF7L2 10 114758349 T 0.228 0.31 Morris et al. 2012
rs10830963 MTNR1B 11 92708710 G 0.260 0.099 Dupuis et al. 2010
rs1552224 ARAP1 11 72433098 A 0.900 0.1 Voight et al. 2010
rs163184 KCNQ1 11 2847069 G 0.373 0.081 Morris et al. 2012
rs2237892 KCNQ1 11 2839751 C 0.851 0.11 Yasuda et al. 2008
rs8181588e KCNQ1 11 2831541 T 0.807 0.19 Wheeler et al. 2017
rs231362 KCNQ1 11 2691471 G 0.729 0.055 Voight et al. 2010
rs757110 KCNJ11 11 17418477 C 0.274 0.068 Gloyn et al. 2003
rs10842994 KLHDC5 12 27965150 C 0.862 0.074 Morris et al. 2012
rs2261181 HMGA2 12 66212318 T 0.156 0.11 Morris et al. 2012
rs7955901 TSPAN8 12 71433293 C 0.434 0.044 Morris et al. 2012
rs1531343 HMGA2 12 66174894 C 0.213 0.1 Voight et al. 2010
rs7957197 HNF1A 12 121460686 T 0.891 0.065 Voight et al. 2010
rs7961581 TSPAN8 12 71663102 C 0.238 0.038 Zeggini et al. 2008
rs1215451f SPRY2 13 80715893 G 0.771 0.083 Morris et al. 2012
rs12899811 VPS33B 15 91544076 G 0.636 0.042 Morris et al. 2012
rs2028299 AP3S2 15 90374257 C 0.270 0.063 Kooner et al. 2011
rs7178572 HMG20A 15 77747190 G 0.526 0.078 Kooner et al. 2011
rs8042680 PRC1 15 91521337 A 0.742 0.051 Voight et al. 2010
rs7202877 CTRB2 16 75247245 T 0.860 0.1 Morris et al. 2012
rs9939609 FTO 16 53820527 A 0.340 0.12 Frayling et al. 2007
rs11651052 HNF1B 17 36102381 A 0.424 0.072 Morris et al. 2012
rs12970134 MC4R 18 57884750 A 0.207 0.052 Morris et al. 2012
rs12454712 BCL2 18 60845884 T 0.624 0.049 Saxena et al. 2012
rs3794991 SUGP1 19 19610596 T 0.088 0.079 Saxena et al. 2012
rs481282 HNF4A 20 42989267 A 0.255 0.05 Kooner et al. 2011
T2D=type 2 diabetes, SNP=single nucleotide polymorphism, CHR=chromosome, POS=position based on human 
genome 19, EAF=effect allele frequency based on global 1000Genomes. aproxy for rs2075423, bproxy for 
rs11717195, cproxy for rs1496653, dproxy for rs13266634, eproxy for fs2237896, fproxy for rs1359790.
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Supplemental Table S2. Genetic variants included in the FG polygenic score
SNP Locus CHR POS FG raising 
allele
EAF β Reference
rs340874 PROX1 1 214159256 C 0.376 0.014 Dupuis et al. 2010
rs1260326 GCKR 2 27730940 C 0.707 0.029 Saxena et al. 2010
rs1371614 DPYSL5 2 27152874 T 0.268 0.016 Manning et al. 2012
rs552976 G6PC2/ABCB11 2 169791438 G 0.748 0.057 Soranzo et al. 2010
rs573225a G6PC2 2 169757541 A 0.855 0.063 Dupuis et al. 2010
rs11708067 ADCY5 3 123065778 A 0.850 0.023 Dupuis et al. 2010
rs10640b AMT 3 49454277 G 0.794 0.011 Scott et al. 2012
rs2877716c ADCY5 3 123094451 C 0.811 0.019 Morris et al. 2012
rs11920090 SLC2A2 3 170717521 T 0.816 0.027 Dupuis et al. 2010
rs4402960 IGF2BP2 3 185511687 T 0.389 0.012 Morris et al. 2012
rs8192675 SLC2A2 3 170724883 T 0.588 0.017 Wheeler et al. 2017
rs9368222 CDKAL1 6 20686996 A 0.269 0.014 Scott et al. 2012
rs10278336 YKT6 7 44245363 A 0.654 0.035 Morris et al. 2012
rs17168486 DGKB 7 14898282 T 0.272 0.031 Morris et al. 2012
rs2191349 DGKB 7 15064309 T 0.572 0.029 Dupuis et al. 2010
rs3824065 YKT6 7 44247258 C 0.655 0.034 Wheeler et al. 2017
rs4607517 GCK 7 44235668 A 0.143 0.064 Dupuis et al. 2012
rs6943153 GRB10 7 50791579 T 0.433 0.015 Scott et al. 2012
rs3802177d SLC30A8 8 118185025 G 0.744 0.028 Morris et al. 2012
rs4841132 PPP1R3B 8 9183596 A 0.093 0.03 Manning et al. 2012
rs983309 PPP1R3B 8 9177732 T 0.152 0.025 Scott et al. 2012
rs10758593 GLIS3 9 4292083 A 0.479 0.016 Morris et al. 2012
rs10811661 CDKN2A/B 9 22134094 T 0.824 0.024 Morris et al. 2012
rs16913693 IKBKAP 9 111680359 T 0.923 0.043 Scott et al. 2012
rs3829109 DNLZ 9 139256766 G 0.790 0.017 Scott et al. 2012
rs4918635e ADRA2A 10 113036224 C 0.718 0.031 Dupuis et al. 2010
rs7903146 TCF7L2 10 114758349 T 0.228 0.022 Morris et al. 2012
rs10501320 MADD 11 47293799 G 0.912 0.025 Strawbridge et al. 2011
rs10830963 MTNR1B 11 92708710 G 0.260 0.078 Dupuis et al. 2010
rs11605924 CRY2 11 45873091 A 0.674 0.022 Dupuis et al. 2010
rs1483121 OR4S1 11 48333360 G 0.959 0.029 Manning et al. 2012
rs1552224 ARAP1 11 72433098 A 0.900 0.02 Voight et al. 2010
rs174550 FADS1 11 61571478 T 0.702 0.02 Dupuis et al. 2010
rs174577 FADS2 11 61604814 C 0.608 0.02 Wheeler et al. 2017
rs7944584 MADD 11 47336320 A 0.878 0.025 Dupuis et al. 2010
rs10747083 P2RX2 12 133041618 A 0.760 0.014 Scott et al. 2012
rs2293941 PDX1 13 28491198 A 0.254 0.02 Manning et al. 2012
rs533873f KL 13 33555587 C 0.320 0.012 Scott et al. 2012
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rs3783347 WARS 14 100839261 G 0.879 0.017 Scott et al. 2012
rs7163757g C2CD4A 15 62391608 C 0.505 0.02 Morris et al. 2012
rs2302593 QPCTL 19 46196634 C 0.576 0.014 Scott et al. 2012
rs6072275 TOP1 20 39743905 A 0.070 0.016 Scott et al. 2012
rs6113722 FOXA2 20 22557099 G 0.900 0.035 Scott et al. 2012
FG=fasting glucose, SNP=single nucleotide polymorphism, CHR=chromosome, POS=position based on human 
genome 19, EAF=effect allele frequency based on global 1000Genomes. aproxy for rs560887, bproxy for 
rs11715915, cproxy for rs11717195, dproxy for rs13266634, eproxy for rs10885122, fproxy for rs576674, gproxy for 
rs4502156.
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Supplemental Table S3. Genetic variants included in the FI polygenic score
SNP Locus CHR POS FI raising 
allele
EAF β Reference
rs2820436 LYPLAL1 1 219640680 C 0.643 0.015 Scott et al. 2012
rs10195252 COBLL1 2 165513091 T 0.603 0.016 Scott et al. 2012
rs1260326 GCKR 2 27730940 C 0.707 0.019 Saxena et al. 2010
rs7578326 IRS1 2 227020653 A 0.714 0.023 Voight et al. 2010
rs9884482 TET2 4 106081636 C 0.350 0.016 Scott et al. 2012
rs459193 C5orf67 5 55806751 G 0.606 0.014 Morris et al. 2012
rs4865796 ARL15 5 53272664 A 0.760 0.015 Mahajan et al. 2014
rs2745353 RSPO3 6 127452935 T 0.552 0.014 Scott et al. 2012
rs1167800 HIP1 7 75176196 A 0.686 0.016 Scott et al. 2012
rs4841132 PPP1R3B 8 9183596 A 0.093 0.03 Manning et al. 2012
rs983309 PPP1R3B 8 9177732 T 0.152 0.029 Scott et al. 2012
rs7903146 TCF7L2 10 114758349 C 0.772 0.018 Morris et al. 2012
rs731839 PEPD 19 33899065 G 0.460 0.014 Scott et al. 2012
FI=fasting insulin, SNP=single nucleotide polymorphism, CHR=chromosome, POS=position based on human 
genome 19, EAF=effect allele frequency based on global 1000Genomes.
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Supplemental Table S4. Association of T2D polygenic score with glipizide and metformin endpoints in 639 white, 
non-Hispanic participants in SUGAR-MGH
N β (95% CI) P
Glipizide endpoint*
Glucose trough (mmol/L)† 436 -0.03 (-0.08, 0.01) 0.18
Glucose AOC (mmol/L*min) 435 12.20 (1.27, 23.13) 0.03
Time to glucose trough (min)† 436 -2.30 (-6.85, 2.25) 0.32
Slope to glucose trough (mmol/L/min)† 436 5.7e-4 (-2.1e-4, 1.4e-3) 0.15
Ln peak insulin (pmol/L)‡ 427 0.04 (-0.02, 0.09) 0.19
Time to insulin peak (min)‡ 427 -5.17 (-9.70, -0.65) 0.03
Slope to insulin peak (pmol/L/min)‡ 423 -0.10 (-0.40, 0.19) 0.50
Metformin endpoint
Fasting glucose V2-V1 (mmol/L)† 590 -0.004 (-0.04, 0.03) 0.56
Glucose AUC (mmol/L*min) 582 14.15 (1.07, 27.24) 0.03
Fasting insulin V2-V1 (pmol/L)‡ 577 -1.64 (-5.17, 1.89) 0.36
Insulin AUC (pmol/L*min) 542 -204.97 (-2123.85, 1713.90) 0.83
Ln HOMA-IR V1 (mmol*pmol/L2) 586 0.05 (-0.02, 0.12) 0.14
Ln HOMA-IR V2 (mmol*pmol/L2) 586 0.02 (-0.05, 0.09) 0.54
HOMA-IR V2-V1 (mmol*pmol/L2) 586 -0.75 (-1.70, 0.20) 0.12
V1=visit 1, V2=visit 2, AOC=area over the curve, AUC=area under the curve. *191 individuals did not meet the 
threshold to receive glipizide or terminated the glipizide challenge early and were excluded from analyses of 
glipizide response. †Adjusted for baseline glucose. ‡Adjusted for ln baseline insulin. Linear regression model was 
adjusted for age, sex, race/ethnicity, and body mass index (BMI). A p-value of <0.008 reflects statistical significance 
after adjustment for multiple testing.
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Supplemental Table S5. Association of T2D polygenic score with glipizide and metformin endpoints in 209 black, 
non-Hispanic participants in SUGAR-MGH
N β (95% CI) P
Glipizide endpoint*
Glucose trough (mmol/L)† 115 0.003 (-0.10, 0.10) 0.96
Glucose AOC (mmol/L*min) 112 3.58 (-17.24, 24.40) 0.73
Time to glucose trough (min)† 115 -14.04 (-25.43, -2.65) 0.01
Slope to glucose trough (mmol/L/min)† 115 1.7e-3 (-8.3e-6, 0.003) 0.05
Ln peak insulin (pmol/L)‡ 104 0.13 (-0.002, 0.25) 0.05
Time to insulin peak (min)‡ 104 -14.60 (-27.34, -1.85) 0.02
Slope to insulin peak (pmol/L/min)‡ 102 -0.05 (-0.88, -0.12) 0.01
Metformin endpoint
Fasting glucose V2-V1 (mmol/L)† 192 -0.06 (-0.13, 0.02) 0.13
Glucose AUC (mmol/L*min) 183 -0.12 (-20.28, 20.04) 0.99
Fasting insulin V2-V1 (pmol/L)‡ 180 -10.62 (-24.24, 2.99) 0.13
Insulin AUC (pmol/L*min) 169 -371.60 (-5059.66, 4316.37) 0.88
Ln HOMA-IR V1 (mmol*pmol/L2) 190 0.008 (-0.13, 0.15) 0.91
Ln HOMA-IR V2 (mmol*pmol/L2) 189 -0.07 (-0.23, 0.09) 0.41
HOMA-IR V2-V1 (mmol*pmol/L2) 189 -2.21 (-5.31, 0.90) 0.16
V1=visit 1, V2=visit 2, AOC=area over the curve, AUC=area under the curve. *96 individuals did not meet the 
threshold to receive glipizide or terminated the glipizide challenge early and were excluded from analyses of 
glipizide response. †Adjusted for baseline glucose. ‡Adjusted for ln baseline insulin. Linear regression model was 
adjusted for age, sex, race/ethnicity, and body mass index (BMI). A p-value of <0.008 reflects statistical significance 
after adjustment for multiple testing.
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Supplemental Table S6. Association of FG polygenic score with glipizide and metformin endpoints in SUGAR-
MGH
N β (95% CI) P
Glipizide endpoint*
Glucose trough (mmol/L)† 639 0.01 (-0.03, 0.05) 0.53
Glucose AOC (mmol/L*min) 633 10.82 (1.42, 20.22) 0.02
Time to glucose trough (min)† 639 3.12 (-1.09, 7.33) 0.15
Slope to glucose trough (mmol/L/min)† 638 -2.3e-4 (-9.2e-4, 4.6e-4) 0.51
Ln peak insulin (pmol/L)‡ 615 -5.1e-4 (-0.05, 0.05) 0.98
Time to insulin peak (min)‡ 615 4.05 (-0.26, 8.35) 0.07
Slope to insulin peak (pmol/L/min)‡ 609 0.005 (-0.23, 0.24) 0.96
Metformin endpoint
Fasting glucose V2-V1 (mmol/L)† 924 0.02 (-0.01, 0.05) 0.24
Glucose AUC (mmol/L*min) 900 4.22 (-5.79, 14.22) 0.41
Fasting insulin V2-V1 (pmol/L)‡ 891 -3.11 (-6.77, 0.55) 0.10
Insulin AUC (pmol/L*min) 831 371.72 (-1742.16, 2485.60) 0.73
Ln HOMA-IR V1 (mmol*pmol/L2) 915 0.03 (-0.02, 0.09) 0.27
Ln HOMA-IR V2 (mmol*pmol/L2) 914 -0.004 (-0.06, 0.06) 0.90
HOMA-IR V2-V1 (mmol*pmol/L2) 914 -0.85 (-1.75, 0.05) 0.06
V1=visit 1, V2=visit 2, AOC=area over the curve, AUC=area under the curve. *351 individuals did not meet the 
threshold to receive glipizide or terminated the glipizide challenge early and were excluded from analyses of 
glipizide response. †Adjusted for baseline glucose. ‡Adjusted for ln baseline insulin. Linear regression model was 
adjusted for age, sex, race/ethnicity, and body mass index (BMI). A p-value of <0.008 reflects statistical significance 
after adjustment for multiple testing.
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Supplemental Table S7. Association of FI polygenic score with glipizide and metformin endpoints in SUGAR-
MGH
N β (95% CI) P
Glipizide endpoint*
Glucose trough (mmol/L)† 639 0.05 (0.007, 0.08) 0.02
Glucose AOC (mmol/L*min) 633 -0.78 (-9.93, 8.38) 0.87
Time to glucose trough (min)† 639 1.38 (-2.65, 5.40) 0.50
Slope to glucose trough (mmol/L/min)† 638 -3.8e-4 (-1.0e-3, 2.7e-4) 0.25
Ln peak insulin (pmol/L)‡ 615 -0.004 (-0.05, 0.05) 0.87
Time to insulin peak (min)‡ 615 1.63 (-2.62, 5.88) 0.45
Slope to insulin peak (pmol/L/min)‡ 609 0.04 (-0.19, 0.27) 0.73
Metformin endpoint
Fasting glucose V2-V1 (mmol/L)† 924 0.02 (-0.01, 0.05) 0.25
Glucose AUC (mmol/L*min) 900 -0.68 (-10.51, 9.14) 0.89
Fasting insulin V2-V1 (pmol/L)‡ 891 -1.67 (-5.30, 1.96) 0.37
Insulin AUC (pmol/L*min) 831 968.00 (-1134.82, 3070.73) 0.37
Ln HOMA-IR V1 (mmol*pmol/L2) 915 0.05 (-0.008, 0.10) 0.09
Ln HOMA-IR V2 (mmol*pmol/L2) 914 0.01 (-0.05, 0.07) 0.68
HOMA-IR V2-V1 (mmol*pmol/L2) 914 -0.59 (-1.47, 0.29) 0.19
V1=visit 1, V2=visit 2, AOC=area over the curve, AUC=area under the curve. *351 individuals did not meet the 
threshold to receive glipizide or terminated the glipizide challenge early and were excluded from analyses of 
glipizide response. †Adjusted for baseline glucose. ‡Adjusted for ln baseline insulin. Linear regression model was 
adjusted for age, sex, race/ethnicity, and body mass index (BMI). A p-value of <0.008 reflects statistical significance 
after adjustment for multiple testing.
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